Strategic Partnerships Target CDMOs and contract manufacturers with outsourcing capabilities in rare disease and neuromuscular programs to secure early manufacturing and scale-up collaborations, leveraging Epirium's existing GMP-focused partnerships for MF-300.

Clinical Progress Monitor and align with Epirium's clinical-stage milestones and IND status for MF-300 to tailor engagement around potential clinical supply, pharmacovigilance support, and regulatory consulting services.

Pipeline Expansion Position adjacent fibrosis and sarcopenia indications as cross-sell opportunities for drug development services, discovery partnerships, or platform licensing to broaden revenue with a modular, IP-protected small molecule platform.

Geographic Footprint Leverage San Diego biotech ecosystem and US/EU clinical conference activity to initiate regional business development efforts, attend industry symposiums, and identify potential customers or investors in neuromuscular and fibrotic therapeutic spaces.

Financial Readiness Propose value-based collaborations and milestone-driven deals aligned with Epirium's mid-range revenue and $86M funding, emphasizing risk-sharing manufacturing, co-development, and translational services to accelerate time-to-value.